Clinical Trial Update: A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating gilteritinib in combination with chemotherapy for pediatric and young adult FLT3-ITD–positive relapsed/refractory acute myeloid leu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia with Flt3-itd Mutation

Drugs mentioned

• Xospata (gilteritinib)

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD) | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2026-01-05